受体酪氨酸激酶抑制剂在恶性胶质瘤中的临床试验进展

Clinical trials of receptor protein-tyrosine kinase inhabitors in malignant glioma

恶性胶质瘤的发生发展与受体酪氨酸激酶（RTK）过表达及其信号转导通路的异常激活密切相关，据此开发出的靶向治疗药物如RTK抑制剂、RTK下游信号通路抑制剂和多靶点抑制剂等能在分子水平上对恶性胶质瘤进行靶向性治疗，其中部分已通过临床试验，并取得良好疗效。

The occurrence and development of malignant glioma are closely related to abnormal overex- pression and activation of receptor tyrosine kinase （RTK） signal transduction pathways. Targeted therapeutic drugs such as RTK inhibitors, RTK downstream signaling pathway inhibitors and multi-target inhibitors can tar- geting treat malignant glioma at molecular level, some of which have been investigated in clinical trials and achieved good therapeutic effects.